Navigation Links
Start Licensing, Inc. Further Strengthens Position in Cloning Industry With New Patents
Date:12/11/2007

New Patents Announced for Methods of Cloning Livestock From Differentiated Donor Cells

AUSTIN, Texas, Dec. 11 /PRNewswire-USNewswire/ -- Start Licensing, Inc. (Start) announced today that the U.S. Patent and Trademark Office has granted U.S. Patent Nos. 7,304,204 and 7,307,198 covering methods of cloning ungulate animals, fetuses and embryos using differentiated cells. These two patents are part of a portfolio of patents and patent applications owned by Roslin Institute that are directed to foundational somatic cell nuclear transfer (SCNT) cloning technology developed at Roslin Institute for the cloning of Dolly the sheep. This portfolio is exclusively licensed to Start for all non-human animal cloning applications.

In addition, the Patent Office has also recently issued notices of allowance for related patent applications in the portfolio, including U.S. Patent Application Nos. 09/650,194 and U.S. 09/989,126 directed to methods of cloning ungulate animals, fetuses and embryos, and of producing mammalian inner cell mass cells. The allowance of these two applications is a direct result of patent interference proceedings initiated at the Patent Office between the 09/650,194 and 09/989,126 applications and U.S. Patents 5,945,577 and 6,234,970, owned by the University of Massachusetts and exclusively licensed to Advanced Cell Technology. A patent interference is a proceeding conducted by the Patent Office when two or more parties claim the same invention in patent filings. Under U.S. law, only the party that is first to invent a new technology is entitled to a patent. The interference proceedings were decided in favor of the 09/650,194 and 09/989,126 applications and judgment was entered against the 5,945,577 and 6,234,970 patents.

Other patents in the portfolio include recently granted U.S. Patent No. 7,232,938 directed to method of cloning ungulates through fusion or microinjection of a quiescent ungulate donor cell. Metabolic changes indicative of cell quiescence include, among other things, the presence of condensed chromatin.

"These patents and allowed applications further strengthen our animal cloning patent position," said Jonathan Thatcher, Chairman of Start Licensing. "The technology covered by the Roslin patents and patent applications has been widely adopted and has increasingly important commercial applications for a wide variety of industries, including agriculture and healthcare. It has been used to clone a broad range of species including cattle, sheep, pigs, goats, horses, mice, rats, rabbits, cats and dogs."

About Start Licensing

Start is a joint venture of Geron Corporation (NASDAQ: GERN) and Exeter Life Sciences, Inc. Start manages and licenses a broad portfolio of intellectual property rights related to animal reproductive technologies, including foundational nuclear transfer cloning technology developed at the Roslin Institute for the cloning of Dolly the sheep. Start's licensees are on the cutting edge of research and product development in food production, medical applications and many other fields.

For more information, call Natalie Garrett, Start Licensing/Turner Strategies, 202-466-9633


'/>"/>
SOURCE Start Licensing, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Underage drinking starts before adolescence
2. Middle School Marks Most Critical Time to Start Ongoing Conversations About Drug and Alcohol Use With Kids
3. Parents Shouldnt Forget Scoliosis Checks as School Starts
4. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
5. Motherhood(R) Maternity Joins March of Dimes to Give Babies a Healthy Start in Life
6. LeMaitre Vascular to Start Italian Sales Force
7. Blunt: Time to Stop the Politics on SCHIP, and Start the Negotiations
8. Congress Starts Hearings on FDAs Control of Tobacco
9. Jane Fonda and Bright Starts(TM) Celebrates Pink Power Moms at Susan G. Komen for the Cure Pink Tie Ball
10. Delay in Start of VNUS Patent Litigation and Court Ruling on Summary Judgment Motion
11. Penn wins $5M to start center for ethical, legal and social implications research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: